FDA Approves TOPIRAMATE — Ajanta Pharma USA Inc.
On August 15, 2023, Ajanta Pharma USA Inc. received FDA approval for its generic form of topiramate, a seizure medication that generated more than $1 billion in U.S. sales last year. This ANDA approval is expected to intensify market competition for the branded leader and drive price erosion in the antiepileptic segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed